Science and Research

Kinases as potential targets for treatment of pulmonary hypertension and right ventricular dysfunction

Pulmonary hypertension (PH) is a progressive pulmonary vasculopathy that causes chronic right ventricular pressure overload and often leads to right ventricular failure. Various kinase inhibitors have been studied in the setting of PH and either improved or worsened the disease, highlighting the importance of understanding the specific role of the respective kinases in a spatiotemporal cellular context. In this review, we will summarize the knowledge on the role of kinases in PH and focus on druggable targets for which certain criteria are met: (a) deregulation of the kinase in PH; (b) small-molecule inhibitors are available (e.g. from the oncology field); (c) preclinical studies have shown their efficacy in PH models; and (d) when available, therapeutic exploitation in human PH has been initiated. Along this line, clinical considerations such as personalized medicine approaches to predict therapy response and adverse side events such as cardiotoxicity together with their clinical management are discussed.

  • Weiss, A.
  • Boehm, M.
  • Egemnazarov, B.
  • Grimminger, F.
  • Savai Pullamsetti, S.
  • Kwapiszewska, G.
  • Schermuly, R. T.
Publication details
DOI: 10.1111/bph.14919
Journal: Br J Pharmacol
Work Type: Review
Location: UGMLC
Disease Area: PH
Partner / Member: JLU, MPI-BN
Access-Number: 31709514
See publication on PubMed

DZL Engagements

chevron-down